Gastroesophageal junction cancer with hepatic metastasis: Effective Treatment using microsphere embolization combined with transarterial infusion chemotherapy. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Zhao, Yu-Qing; Hu, Hong-Tao; Zhao, Yan; Li, Hai-liang; Guo, Chen-yang; Yao, Quan-jun; Geng, Xiang; Cheng, Hong-Tao; Jiang, Li; Yuan, Hang
• Is Part Of: Digestive and liver disease. Volume 53:Issue 11(2021)
• Page Start: 1499
• Page End: 1505
• Publication Date: 2021-11
• Subjects: Gastroesophageal junction cancer -- Intra-arterial infusion chemotherapy -- Microsphere -- Embolization; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2021.03.023
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Purpose: To determine the safety and efficacy of microsphere embolization plus transarterial infusion chemotherapy for the treatment of gastroesophageal junction cancer with hepatic metastasis. Methods: Sixty patients with gastroesophageal junction cancer and hepatic metastasis were randomly divided into two groups: group A (treatment group), which was treated with transarterial infusion chemotherapy plus microsphere embolization for gastroesophageal cancer, and with transarterial chemoembolization for hepatic metastasis; and group B (control group), which was treated with transarterial infusion chemotherapy for gastroesophageal cancer, and with transarterial chemoembolization for hepatic metastasis. The chemotherapy regimen used consisted of oxaliplatin plus FUDR. The embolization agent used for gastroesophageal cancer and the hepatic metastasis were Embosphere and ultra-liquefied lipiodol, respectively. Results: The median survival time of patients in group A was 19 months, with survival rates at 12, 18, and 24 months of 93.3%, 60.0%, and 23.3%, respectively. The median survival time of patients in group B was 13 months, with survival rates at 12, 18, and 24 months of 60.0%, 30.0%, and 3.3%, respectively. There was a significant difference in survival between the two groups ( P = 0.00). One month after treatment, the severity of dysphagia was significantly less in group A, as compared to that in group B ( p < 0.001). Conclusion: Treatment of gastroesophageal junction cancer with hepatic metastasis by transarterial infusion chemotherapy plus microsphere embolization can rapidly reduce tumor size near the gastroesophageal junction. This treatment is an effective therapeutic option for these patients as it can relieve dysphagia and improve long-term survival rate.